Inflammation in Vascular Disease
Launched by GÖTEBORG UNIVERSITY · Nov 5, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Inflammation in Vascular Disease," is studying how inflammation in the body might affect heart and blood vessel health, particularly in conditions like atherosclerosis, where arteries become narrowed due to plaque buildup. Researchers believe that low-level inflammation could play a significant role in causing problems like vascular dysfunction and heart disease. The study aims to better understand this connection to improve treatments for these conditions.
To participate in this trial, you need to be between 65 and 74 years old and scheduled for vascular surgery. It's important that you can understand the information provided about the study and that you give your consent to take part. Unfortunately, people under 18 or those currently involved in other drug studies cannot join. If you decide to participate, you'll receive more information on what to expect throughout the study process. This research is a valuable step towards finding better ways to treat cardiovascular diseases linked to inflammation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient is planned to undergo vascular surgery.
- • Signed informed consent has been obtained from the patient.
- Exclusion Criteria:
- • Patient has difficulty to understand information.
- • Patients under 18 years of age.
- • Patients participating in any drug-related study.
About Göteborg University
Göteborg University, a leading academic institution in Sweden, is committed to advancing healthcare through innovative research and clinical trials. With a strong focus on interdisciplinary collaboration, the university leverages its extensive expertise in various fields, including medicine, pharmacology, and social sciences, to address pressing health challenges. By sponsoring clinical trials, Göteborg University aims to contribute to the development of new therapies and improve patient outcomes, while adhering to the highest ethical standards and regulatory requirements. Their dedication to rigorous scientific inquiry and community engagement positions them as a pivotal player in the global health research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gothenburg, Vastragotaland, Sweden
Patients applied
Trial Officials
Jan Boren, MD, PhD
Study Director
The University of Gothenburg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials